Radiopharm Theranostics (RDPTF) Revenue (2024 - 2026)
Radiopharm Theranostics' (RDPTF) quarterly Revenue came in at $242356.2 in Q2 2026, up 257.81% year-over-year from $67733.5 in Q2 2025, and up 257.81% quarter-over-quarter from $67733.5 in Q2 2025.
Powered by 
Analysis
Radiopharm Theranostics (RDPTF) Revenue (2024 - 2026) Analysis & Trends
Radiopharm Theranostics (RDPTF) has reported Revenue for 3 consecutive years, with $242356.2 the latest figure, recorded in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 10.05 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 7.80 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 3.33 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 4.29 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 1.52 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 145.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 2.74 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Radiopharm Theranostics | 23.65 Mn | 23.60 Mn | -92,644.38 | 242,356.23 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 242,356.23 |
| Jun 30, 2025 | 67,733.50 |
| Jun 30, 2024 | 236,727.53 |